Lung Adenocarcinoma Harboring Concomitant EGFR Mutation and EML4-ALK Fusion That Benefits From Three Kinds of Tyrosine Kinase Inhibitors: A Case Report and Literature Review
- 17 November 2014
- journal article
- case report
- Published by Elsevier BV in Clinical Lung Cancer
- Vol. 16 (2), e5-e9
- https://doi.org/10.1016/j.cllc.2014.11.001
Abstract
No abstract availableKeywords
Funding Information
- Key Technologies R&D Program of Guangzhou (2011Y2-00014)
- Key Laboratory Program of Guangdong (2012A061400006)
- Guangdong Department of Science & Technology Translational Medicine Center (2011A080300002)
This publication has 16 references indexed in Scilit:
- Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted DrugsJAMA, 2014
- Lung Cancers with Concomitant EGFR Mutations and ALK Rearrangements: Diverse Responses to EGFR-TKI and Crizotinib in Relation to Diverse Receptors PhosphorylationClinical Cancer Research, 2014
- A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALKfusion geneBMC Cancer, 2012
- Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocationLung Cancer, 2012
- Lung Adenocarcinoma with Concurrent Exon 19 EGFR Mutation and ALK Rearrangement Responding to ErlotinibJournal of Thoracic Oncology, 2011
- A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase InhibitorsCancer Research, 2011
- EGFR and EML4-ALK gene mutations in NSCLC: A case report of erlotinib-resistant patient with both concomitant mutationsLung Cancer, 2011
- Good Response to Gefitinib in Lung Adenocarcinoma Harboring Coexisting EML4-ALK Fusion Gene and EGFR MutationJournal of Thoracic Oncology, 2010
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALKJournal of Clinical Oncology, 2009
- Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancerNature, 2007